BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23113470)

  • 1. Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.
    Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Kim TG; Park CW; Kim YJ
    Eur J Haematol; 2013 Feb; 90(2):111-20. PubMed ID: 23113470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype.
    Wudhikarn K; Van Rheeden R; Leopold C; Rattanaumpawan P; Gingrich R; de Magalhaes Silverman M
    Eur J Haematol; 2012 Oct; 89(4):294-301. PubMed ID: 22762733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
    Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
    Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
    Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
    Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
    Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
    Sohn SK; Moon JH
    Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Al-Ali HK; Brand R; van Biezen A; Finke J; Boogaerts M; Fauser AA; Egeler M; Cahn JY; Arnold R; Biersack H; Niederwieser D; de Witte T
    Leukemia; 2007 Sep; 21(9):1945-51. PubMed ID: 17611571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
    de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
    Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
    Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
    Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
    Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.